{"id":745734,"date":"2018-04-16T08:30:00","date_gmt":"2018-04-16T08:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a\/"},"modified":"2025-11-07T01:27:23","modified_gmt":"2025-11-07T06:27:23","slug":"mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a\/","title":{"rendered":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Pemetrexed (ALIMTA\u00ae) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study"},"content":{"rendered":"<p class=\"bwalignc\">       KEYTRUDA Combination Improved Overall Survival in Patients Regardless        of PD-L1 Expression, Including Patients Who Tested Negative for PD-L1     <\/p>\n<p class=\"bwalignc\">       Results Presented Today at AACR 2018 and Published in The New        England Journal of Medicine Also Show Significant Improvement in        Progression-Free Survival, with Risk of Progression or Death Reduced by        Nearly Half     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced results from KEYNOTE-189, a pivotal Phase 3 trial<br \/>\n      evaluating KEYTRUDA<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>, Merck\u2019s anti-PD-1 therapy, in<br \/>\n      combination with pemetrexed (ALIMTA<sup>\u00ae<\/sup>) and cisplatin or<br \/>\n      carboplatin for the first-line treatment of metastatic nonsquamous<br \/>\n      non-small cell lung cancer (NSCLC). Findings showed that the<br \/>\n      KEYTRUDA-pemetrexed-platinum chemotherapy combination significantly<br \/>\n      improved overall survival (OS), reducing the risk of death by half<br \/>\n      compared with chemotherapy alone (HR=0.49 [95% CI, 0.38-0.64];<br \/>\n      p&lt;0.00001). In pre-specified exploratory analyses, an OS benefit was<br \/>\n      observed regardless of PD-L1 expression in the three PD-L1 categories<br \/>\n      that were evaluated, including: patients whose tumors were negative for<br \/>\n      PD-L1 (HR=0.59 [95% CI, 0.38-0.92]); patients whose tumors had PD-L1<br \/>\n      tumor proportion scores (TPS) of 1-49 percent (HR=0.55 [95% CI,<br \/>\n      0.34-0.90]); and patients who had a TPS of greater than or equal to 50<br \/>\n      percent (HR=0.42 [95% CI, 0.26-0.68]). The addition of KEYTRUDA to<br \/>\n      pemetrexed plus platinum chemotherapy also achieved a significant<br \/>\n      improvement in progression-free survival (PFS), with a reduction in the<br \/>\n      risk of progression or death of nearly half for patients in the KEYTRUDA<br \/>\n      combination arm, compared with chemotherapy alone (HR=0.52 [95% CI,<br \/>\n      0.43-0.64]; p&lt;0.00001). A PFS improvement in the KEYTRUDA combination<br \/>\n      group was observed in patients whose tumors were negative for PD-L1<br \/>\n      (HR=0.75 [95% CI, 0.53-1.05]); patients with a TPS of 1-49 percent<br \/>\n      (HR=0.55 [95% CI, 0.37-0.81]); and patients with a TPS greater than or<br \/>\n      equal to 50 percent (HR=0.36 [95% CI, 0.25-0.52]). These results are<br \/>\n      being presented today in a plenary session at the American Association<br \/>\n      for Cancer Research (AACR) Annual Meeting 2018 (Abstract #CT075), with<br \/>\n      simultaneous publication in <i>The New England Journal of Medicine<\/i>.\n    <\/p>\n<p>\n      \u201cIn this trial, KEYTRUDA in combination with pemetrexed and platinum<br \/>\n      chemotherapy, compared with chemotherapy alone, prolonged overall<br \/>\n      survival and progression-free survival in patients with advanced<br \/>\n      nonsquamous non-small cell lung cancer regardless of PD-L1 expression,\u201d<br \/>\n      said Dr. Leena Gandhi, director of thoracic medical oncology at NYU<br \/>\n      Langone\u2019s Perlmutter Cancer Center and lead author of <i>The New England<br \/>\n      Journal of Medicine<\/i> paper. \u201cThere is good scientific rationale for<br \/>\n      combining KEYTRUDA with pemetrexed and platinum chemotherapy, and these<br \/>\n      clinical data now suggest this combination as a new standard of care for<br \/>\n      the first-line treatment of these nonsquamous non-small cell lung cancer<br \/>\n      patients.\u201d\n    <\/p>\n<p>\n      \u201cOur goal is to extend the lives of patients with lung cancer, and the<br \/>\n      unambiguous survival findings from KEYNOTE-189 showing the risk of death<br \/>\n      was reduced by half in the KEYTRUDA arm are important not only for<br \/>\n      patients but also for the medical community,\u201d said Dr. Roger M.<br \/>\n      Perlmutter, president, Merck Research Laboratories. \u201cThe results of this<br \/>\n      trial have the potential to change the treatment paradigm for patients<br \/>\n      with nonsquamous non-small cell lung cancer in the first-line setting,<br \/>\n      including patients whose tumors are either PD-L1 negative or are<br \/>\n      untested.\u201d\n    <\/p>\n<p>\n      KEYTRUDA is the first immunotherapy to significantly extend survival of<br \/>\n      patients with nonsquamous NSCLC in combination with chemotherapy as a<br \/>\n      first-line treatment. KEYNOTE-189 is the confirmatory trial for<br \/>\n      KEYNOTE-021 (Cohort G), a Phase 2 study that made KEYTRUDA the only<br \/>\n      FDA-approved anti-PD-1 therapy in combination with chemotherapy<br \/>\n      (pemetrexed plus carboplatin) for the first-line treatment of patients<br \/>\n      with metastatic nonsquamous NSCLC, regardless of PD-L1 expression. Merck<br \/>\n      is working to submit data from KEYNOTE-189 to regulatory agencies in the<br \/>\n      United States and around the world.\n    <\/p>\n<p>\n      Merck has an extensive clinical development program in lung cancer and<br \/>\n      is advancing multiple registration-enabling studies with KEYTRUDA in<br \/>\n      combination with other treatments and as monotherapy. The program, which<br \/>\n      is comprised of nearly 9,000 patients across 15 clinical studies, is<br \/>\n      evaluating KEYTRUDA across multiple settings and stages of the disease.\n    <\/p>\n<p>\n      \u201cThe reality is, there remains a significant need for treatment options<br \/>\n      for patients with lung cancer. At the Bonnie J. Addario Lung Cancer<br \/>\n      Foundation (ALCF), we are devoted exclusively to eradicating lung cancer<br \/>\n      through research, early detection, education and treatment. And, the<br \/>\n      survival benefit achieved by the KEYTRUDA combination in the KEYNOTE-189<br \/>\n      study represents a meaningful advance and may offer hope for patients<br \/>\n      newly diagnosed with one of the most common and deadly cancers,\u201d said<br \/>\n      Bonnie J. Addario, a 14-year lung cancer survivor and ALCF founder.\n    <\/p>\n<p>\n      <b>Additional Data and Safety Information from KEYNOTE-189 (Abstract<br \/>\n      #CT075)<\/b><br \/>\n<br \/>KEYNOTE-189, a randomized, double-blind,<br \/>\n      placebo-controlled, Phase 3 study, evaluated KEYTRUDA in combination<br \/>\n      with pemetrexed and cisplatin or carboplatin, compared with pemetrexed<br \/>\n      and cisplatin or carboplatin alone, in 616 untreated patients with<br \/>\n      metastatic nonsquamous NSCLC, regardless of PD-L1 expression. Patients<br \/>\n      had no sensitizing <i>EGFR<\/i> or <i>ALK<\/i> genomic tumor aberrations,<br \/>\n      and had not previously received systemic therapy for advanced disease.<br \/>\n      The dual primary endpoints were OS and PFS; secondary endpoints include<br \/>\n      overall response rate (ORR) and duration of response (DOR).\n    <\/p>\n<p>\n      With a median follow-up of 10.5 months (range, 0.2-20.4), KEYTRUDA in<br \/>\n      combination with pemetrexed and a platinum chemotherapy demonstrated<br \/>\n      superior improvements in OS, with a 51 percent reduction in the risk of<br \/>\n      death, compared with pemetrexed plus platinum chemotherapy alone<br \/>\n      (HR=0.49 [95% CI, 0.38-0.64]; p&lt;0.00001). This finding includes the 50<br \/>\n      percent of patients randomized to the chemotherapy alone group who<br \/>\n      discontinued all study therapy (n=170) and went on to receive subsequent<br \/>\n      anti-PD-1 or PD-L1 therapy, including 67 patients who received KEYTRUDA<br \/>\n      monotherapy as part of study crossover. Median OS was not reached in the<br \/>\n      KEYTRUDA combination group (95% CI, not estimable) and was 11.3 months<br \/>\n      in the chemotherapy alone group (95% CI, 8.7-15.1). In the study, 69.2<br \/>\n      percent of patients were estimated to be alive at 12 months in the<br \/>\n      KEYTRUDA treatment group (95% CI, 64.1-73.8%) compared with 49.4 percent<br \/>\n      in the chemotherapy alone group (95% CI, 42.1-56.2%).\n    <\/p>\n<p>\n      In KEYNOTE-189 there was also a significant improvement in PFS for<br \/>\n      KEYTRUDA in combination with pemetrexed and platinum chemotherapy with a<br \/>\n      48 percent reduction in the risk of progression or death compared with<br \/>\n      pemetrexed plus platinum chemotherapy alone (HR=0.52 [95% CI,<br \/>\n      0.43-0.64]; p&lt;0.00001). The median PFS was 8.8 months for the KEYTRUDA<br \/>\n      combination (95% CI, 7.6-9.2) compared with 4.9 months for chemotherapy<br \/>\n      alone (95% CI, 4.7-5.5). The percentage of patients who were alive with<br \/>\n      no progression of disease at 12 months was 34.1 percent in the KEYTRUDA<br \/>\n      combination group (95% CI, 28.8-39.5%), which was nearly double the<br \/>\n      percentage of the pemetrexed plus platinum chemotherapy group (17.3<br \/>\n      percent [95% CI, 12.0-23.5%]). In addition, improvements in OS and PFS<br \/>\n      were observed in other patient subgroups evaluated, including age, sex,<br \/>\n      EGOG performance-status score, smoking status, brain metastases at<br \/>\n      baseline and type of platinum chemotherapy prescribed (carboplatin or<br \/>\n      cisplatin).\n    <\/p>\n<p>\n      In the study, KEYTRUDA plus pemetrexed and a platinum chemotherapy also<br \/>\n      showed an ORR that was more than double the ORR of chemotherapy alone<br \/>\n      (47.6 percent [95% CI, 42.6-52.5%] compared to 18.9 percent [95% CI,<br \/>\n      13.8-25.0%], respectively, p&lt;0.00001). Among patients in the KEYTRUDA<br \/>\n      arm, the median duration of response was 11.2 months (range, 1.1+ to<br \/>\n      18.0+ months) compared with 7.8 months in the chemotherapy alone group<br \/>\n      (range, 2.1+ to 16.4+ months). The improvement in response rate occurred<br \/>\n      in all PD-L1 patient subgroups.\n    <\/p>\n<p>\n      The safety of KEYTRUDA was consistent with what has been seen in<br \/>\n      previous trials among patients with metastatic NSCLC. Grade 3-5 adverse<br \/>\n      events from any cause occurred in 67.2 percent of patients in the<br \/>\n      KEYTRUDA plus pemetrexed and platinum chemotherapy group and 65.8<br \/>\n      percent in the chemotherapy alone arm. Adverse events of any grade and<br \/>\n      from any cause with an incidence of 15 percent or more in the KEYTRUDA<br \/>\n      group were nausea (55.6%), anemia (46.2%), fatigue (40.7%), constipation<br \/>\n      (34.8%), diarrhea (30.9%), decreased appetite (28.1%), neutropenia<br \/>\n      (27.2%), vomiting (24.2%), cough (21.5%), dyspnea (21.2%), asthenia<br \/>\n      (20.5%), rash (20.2%), pyrexia (19.5%), edema peripheral (19.3%),<br \/>\n      thrombocytopenia (18.0%) and increased lacrimation (17.0%). The most<br \/>\n      common immune-mediated adverse events of any grade in patients receiving<br \/>\n      KEYTRUDA plus pemetrexed and platinum chemotherapy were hypothyroidism<br \/>\n      (6.7%), pneumonitis (4.4%), hyperthyroidism (4.0%), infusion reactions<br \/>\n      (2.5%), colitis (2.2%), severe skin toxicity (2.0%), nephritis (1.7%)<br \/>\n      and hepatitis (1.2%). There were three treatment-related deaths from<br \/>\n      pneumonitis in the KEYTRUDA plus pemetrexed and platinum chemotherapy<br \/>\n      group.\n    <\/p>\n<p>\n      <b>About KEYNOTE-189<\/b><br \/>\n<br \/>KEYNOTE-189 (ClinicalTrials.gov,<br \/>\n      NCT02578680) enrolled 616 patients who were randomized 2:1 to one of two<br \/>\n      treatment groups, and were treated until disease progression,<br \/>\n      unacceptable toxicity, physician decision or consent withdrawal, as<br \/>\n      follows:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        KEYTRUDA (200 mg fixed dose every three weeks) plus pemetrexed (500<br \/>\n        mg\/m<sup>2<\/sup>) (with vitamin supplementation) plus cisplatin (75<br \/>\n        mg\/m<sup>2<\/sup>) or carboplatin AUC 5 mg\/mL\/min on day 1 every three<br \/>\n        weeks (Q3W) for four cycles, followed by KEYTRUDA 200 mg plus<br \/>\n        pemetrexed (500 mg\/m<sup>2<\/sup>) Q3W; or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Saline placebo plus pemetrexed (500 mg\/m<sup>2<\/sup>) (with vitamin<br \/>\n        supplementation) plus cisplatin (75 mg\/m<sup>2<\/sup>) or carboplatin<br \/>\n        AUC 5 mg\/mL\/min on day 1 every three weeks (Q3W) for four cycles,<br \/>\n        followed by placebo plus pemetrexed (500 mg\/m<sup>2<\/sup>) Q3W.\n      <\/li>\n<\/ul>\n<p>\n      Patients on the control arm who experienced disease progression,<br \/>\n      verified by central independent review, were permitted to undergo<br \/>\n      treatment assignment unblinding and crossover to receive open-label<br \/>\n      KEYTRUDA. The KEYNOTE-189 study was conducted in collaboration with Eli<br \/>\n      Lilly and Company, the makers of pemetrexed (ALIMTA).\n    <\/p>\n<p>\n      <b>About Lung Cancer<\/b><br \/>\n<br \/>Lung cancer, which forms in the tissues of<br \/>\n      the lungs, usually within cells lining the air passages, is the leading<br \/>\n      cause of cancer death worldwide. Each year, more people die of lung<br \/>\n      cancer than die of colon, breast and prostate cancers combined. The two<br \/>\n      main types of lung cancer are non-small cell and small cell. NSCLC is<br \/>\n      the most common type of lung cancer, accounting for about 85 percent of<br \/>\n      all cases. The five-year survival rate for patients diagnosed in the<br \/>\n      United States with any stage of lung cancer is estimated to be 18<br \/>\n      percent.\n    <\/p>\n<p>\n      <b>Merck Investor Webcast<\/b><br \/>\n<br \/>Merck will hold a live investor audio<br \/>\n      webcast in conjunction with the AACR 2018 Annual Meeting on Monday,<br \/>\n      April 16 at 6:45 p.m. CDT (7:45 p.m. EDT).&nbsp;Those interested in<br \/>\n      participating can register and join <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.on24.com%2FeventRegistration%2FEventLobbyServlet%3Ftarget%3Dreg20.jsp%26referrer%3Dhttp%253A%252F%252Finvestors.merck.com%252Fevents-and-presentations%252Fevent-details%252F2018%252FMerck--Co-Inc-Oncology-Event-at-AACR-2018%252Fdefault.aspx%26eventid%3D1645158%26sessionid%3D1%26key%3DF9B254E6894C96D690A09ECB3CFA96DB%26regTag%3D%26sourcepage%3Dregister&amp;esheet=51788998&amp;newsitemid=20180416005456&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=6484bad780929d5afe23a7c6e4398636\" rel=\"nofollow\">here<\/a>.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae&nbsp;<\/b><br \/>\n<\/sup><br \/>\n<b>(pembrolizumab)<br \/>\n      Injection 100mg<\/b><br \/>\n<br \/>KEYTRUDA is an anti-PD-1 therapy that works by<br \/>\n      increasing the ability of the body\u2019s immune system to help detect and<br \/>\n      fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that<br \/>\n      blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2,<br \/>\n      thereby activating T lymphocytes which may affect both tumor cells and<br \/>\n      healthy cells.\n    <\/p>\n<p>\n      Merck has the industry\u2019s largest immuno-oncology clinical research<br \/>\n      program, which currently involves more than 700 trials studying KEYTRUDA<br \/>\n      across a wide variety of cancers and treatment settings. The KEYTRUDA<br \/>\n      clinical program seeks to understand the role of KEYTRUDA across cancers<br \/>\n      and the factors that may predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including exploring several different<br \/>\n      biomarkers.\n    <\/p>\n<p>\n      <b>KEYTRUDA (pembrolizumab) Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i><br \/>\n<br \/>KEYTRUDA is indicated for the treatment of patients<br \/>\n      with unresectable or metastatic melanoma at a fixed dose of 200 mg every<br \/>\n      three weeks until disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i><br \/>\n<br \/>KEYTRUDA, as a single agent, is indicated for<br \/>\n      the first-line treatment of patients with metastatic non-small cell lung<br \/>\n      cancer (NSCLC) whose tumors have high PD-L1 expression [tumor proportion<br \/>\n      score (TPS) \u226550%] as determined by an FDA-approved test, with no EGFR or<br \/>\n      ALK genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i><br \/>\n<br \/>KEYTRUDA is indicated for the treatment<br \/>\n      of patients with recurrent or metastatic head and neck squamous cell<br \/>\n      carcinoma (HNSCC) with disease progression on or after<br \/>\n      platinum-containing chemotherapy. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials. In HNSCC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i><br \/>\n<br \/>KEYTRUDA is indicated for the<br \/>\n      treatment of adult and pediatric patients with refractory classical<br \/>\n      Hodgkin lymphoma (cHL), or who have relapsed after three or more prior<br \/>\n      lines of therapy. This indication is approved under accelerated approval<br \/>\n      based on tumor response rate and durability of response. Continued<br \/>\n      approval for this indication may be contingent upon verification and<br \/>\n      description of clinical benefit in the confirmatory trials. In adults<br \/>\n      with cHL, KEYTRUDA is administered at a fixed dose of 200 mg every three<br \/>\n      weeks until disease progression or unacceptable toxicity, or up to 24<br \/>\n      months in patients without disease progression. In pediatric patients<br \/>\n      with cHL, KEYTRUDA is administered at a dose of 2 mg\/kg (up to a maximum<br \/>\n      of 200 mg) every three weeks until disease progression or unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i><br \/>\n<br \/>KEYTRUDA is indicated for the treatment<br \/>\n      of patients with locally advanced or metastatic urothelial carcinoma who<br \/>\n      are not eligible for cisplatin-containing chemotherapy. This indication<br \/>\n      is approved under accelerated approval based on tumor response rate and<br \/>\n      duration of response. Continued approval for this indication may be<br \/>\n      contingent upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who have disease progression<br \/>\n      during or following platinum-containing chemotherapy or within 12 months<br \/>\n      of neoadjuvant or adjuvant treatment with platinum-containing<br \/>\n      chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i><br \/>\n<br \/>KEYTRUDA is<br \/>\n      indicated for the treatment of adult and pediatric patients with<br \/>\n      unresectable or metastatic microsatellite instability-high (MSI-H) or<br \/>\n      mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      children with MSI-H cancer, KEYTRUDA is administered at a dose of 2<br \/>\n      mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Gastric Cancer<\/i><br \/>\n<br \/>KEYTRUDA is indicated for the treatment of<br \/>\n      patients with recurrent locally advanced or metastatic gastric or<br \/>\n      gastroesophageal junction (GEJ) adenocarcinoma whose tumors express<br \/>\n      PD-L1 [Combined Positive Score (CPS) \u22651] as determined by an<br \/>\n      FDA-approved test, with disease progression on or after two or more<br \/>\n      prior lines of therapy including fluoropyrimidine- and<br \/>\n      platinum-containing chemotherapy and if appropriate, HER2\/neu-targeted<br \/>\n      therapy. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and durability of response. Continued approval for<br \/>\n      this indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The recommended dose of<br \/>\n      KEYTRUDA is 200 mg every three weeks until disease progression,<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<br \/>KEYTRUDA<br \/>\n      can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. The incidence of new or worsening hypothyroidism was<br \/>\n      higher in patients with HNSCC, occurring in 28 (15%) of 192 patients<br \/>\n      with HNSCC, including Grade 3 (0.5%) hypothyroidism. Thyroiditis<br \/>\n      occurred in 16 (0.6%) of 2799 patients receiving KEYTRUDA, including<br \/>\n      Grade 2 (0.3%) thyroiditis. Monitor patients for changes in thyroid<br \/>\n      function (at the start of treatment, periodically during treatment, and<br \/>\n      as indicated based on clinical evaluation) and for clinical signs and<br \/>\n      symptoms of thyroid disorders. Administer replacement hormones for<br \/>\n      hypothyroidism and manage hyperthyroidism with thionamides and<br \/>\n      beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic<br \/>\n      epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative<br \/>\n      dermatitis, and bullous pemphigoid, can occur. Monitor patients for<br \/>\n      suspected severe skin reactions and based on the severity of the adverse<br \/>\n      reaction, withhold or permanently discontinue KEYTRUDA and administer<br \/>\n      corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA<br \/>\n      and refer the patient for specialized care for assessment and treatment.<br \/>\n      If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. These immune-mediated reactions may occur in any organ<br \/>\n      system. For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures<br \/>\n      arising in a patient with inflammatory foci in brain parenchyma. In<br \/>\n      addition, myelitis and myocarditis were reported in other clinical<br \/>\n      trials, including classical Hodgkin lymphoma, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA. Treatment with KEYTRUDA may increase the risk of rejection<br \/>\n      in solid organ transplant recipients. Consider the benefit of treatment<br \/>\n      with KEYTRUDA vs the risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 6 (0.2%) of 2799 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions, including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after being treated with KEYTRUDA. Of 23 patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after treatment with KEYTRUDA<br \/>\n      on any trial, 6 patients (26%) developed graft-versus-host disease<br \/>\n      (GVHD), one of which was fatal, and 2 patients (9%) developed severe<br \/>\n      hepatic veno-occlusive disease (VOD) after reduced-intensity<br \/>\n      conditioning, one of which was fatal. Cases of fatal hyperacute GVHD<br \/>\n      after allogeneic HSCT have also been reported in patients with lymphoma<br \/>\n      who received a PD-1 receptor\u2013blocking antibody before transplantation.\n    <\/p>\n<p>\n      These complications may occur despite intervening therapy between PD-1<br \/>\n      blockade and allogeneic HSCT. Follow patients closely for early evidence<br \/>\n      of transplant-related complications such as hyperacute GVHD, severe<br \/>\n      (Grade 3 to 4) acute GVHD, steroid-requiring febrile syndrome, hepatic<br \/>\n      VOD, and other immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      In clinical trials in patients with multiple myeloma, the addition of<br \/>\n      KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in<br \/>\n      increased mortality. Treatment of these patients with a PD-1 or PD-L1<br \/>\n      blocking antibody in this combination is not recommended outside of<br \/>\n      controlled clinical trials.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 21% of patients; the most common (\u22651%) was diarrhea<br \/>\n      (2.5%). The most common adverse reactions with KEYTRUDA vs ipilimumab<br \/>\n      were fatigue (28% vs 28%), diarrhea (26% with KEYTRUDA), rash (24% vs<br \/>\n      23%), and nausea (21% with KEYTRUDA). Corresponding incidence rates are<br \/>\n      listed for ipilimumab only for those adverse reactions that occurred at<br \/>\n      the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse<br \/>\n      reactions in 8% of 682 patients with metastatic NSCLC. The most common<br \/>\n      adverse event resulting in permanent discontinuation of KEYTRUDA was<br \/>\n      pneumonitis (1.8%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 23% of patients; the most common (\u22651%) were<br \/>\n      diarrhea (1%), fatigue (1.3%), pneumonia (1%), liver enzyme elevation<br \/>\n      (1.2%), decreased appetite (1.3%), and pneumonitis (1%). The most common<br \/>\n      adverse reactions (occurring in at least 20% of patients and at a higher<br \/>\n      incidence than with docetaxel) were decreased appetite (25% vs 23%),<br \/>\n      dyspnea (23% vs 20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      In KEYNOTE-021(G1), when KEYTRUDA was administered in combination with<br \/>\n      carboplatin and pemetrexed (carbo\/pem) in advanced nonsquamous NSCLC,<br \/>\n      KEYTRUDA was discontinued in 10% of 59 patients. The most common adverse<br \/>\n      reaction resulting in discontinuation of KEYTRUDA (\u22652%) was acute kidney<br \/>\n      injury (3.4%). Adverse reactions leading to interruption of KEYTRUDA<br \/>\n      occurred in 39% of patients; the most common (\u22652%) were fatigue (8%),<br \/>\n      neutrophil count decreased (8%), anemia (5%), dyspnea (3.4%), and<br \/>\n      pneumonitis (3.4%). The most common adverse reactions (\u226520%) with<br \/>\n      KEYTRUDA compared to carbo\/pem alone were fatigue (71% vs 50%), nausea<br \/>\n      (68% vs 56%), constipation (51% vs 37%), rash (42% vs 21%), vomiting<br \/>\n      (39% vs 27%), dyspnea (39% vs 21%), diarrhea (37% vs 23%), decreased<br \/>\n      appetite (31% vs 23%), headache (31% vs 16%), cough (24% vs 18%),<br \/>\n      dizziness (24% vs 16%), insomnia (24% vs 15%), pruritus (24% vs 4.8%),<br \/>\n      peripheral edema (22% vs 18%), dysgeusia (20% vs 11%), alopecia (20% vs<br \/>\n      3.2%), upper respiratory tract infection (20% vs 3.2%), and arthralgia<br \/>\n      (15% vs 24%). This study was not designed to demonstrate a statistically<br \/>\n      significant difference in adverse reaction rates for KEYTRUDA as<br \/>\n      compared to carbo\/pem alone for any specified adverse reaction.\n    <\/p>\n<p>\n      In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      17% of 192 patients with HNSCC. Serious adverse reactions occurred in<br \/>\n      45% of patients. The most frequent serious adverse reactions reported in<br \/>\n      at least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue,<br \/>\n      decreased appetite, and dyspnea. Adverse reactions occurring in patients<br \/>\n      with HNSCC were generally similar to those occurring in patients with<br \/>\n      melanoma or NSCLC, with the exception of increased incidences of facial<br \/>\n      edema (10% all Grades; 2.1% Grades 3 or 4) and new or worsening<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5%<br \/>\n      of 210 patients with cHL, and treatment was interrupted due to adverse<br \/>\n      reactions in 26% of patients. Fifteen percent (15%) of patients had an<br \/>\n      adverse reaction requiring systemic corticosteroid therapy. Serious<br \/>\n      adverse reactions occurred in 16% of patients. The most frequent serious<br \/>\n      adverse reactions (\u22651%) included pneumonia, pneumonitis, pyrexia,<br \/>\n      dyspnea, GVHD, and herpes zoster. Two patients died from causes other<br \/>\n      than disease progression; one from GVHD after subsequent allogeneic HSCT<br \/>\n      and one from septic shock. The most common adverse reactions (occurring<br \/>\n      in \u226520% of patients) were fatigue (26%), pyrexia (24%), cough (24%),<br \/>\n      musculoskeletal pain (21%), diarrhea (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      11% of 370 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reactions (in \u226520% of patients) were<br \/>\n      fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),<br \/>\n      constipation (21%), rash (21%), and diarrhea (20%). Eighteen patients<br \/>\n      (5%) died from causes other than disease progression. Five patients<br \/>\n      (1.4%) who were treated with KEYTRUDA experienced sepsis which led to<br \/>\n      death, and 3 patients (0.8%) experienced pneumonia which led to death.<br \/>\n      Adverse reactions leading to interruption of KEYTRUDA occurred in 22% of<br \/>\n      patients; the most common (\u22651%) were liver enzyme increase, diarrhea,<br \/>\n      urinary tract infection, acute kidney injury, fatigue, joint pain, and<br \/>\n      pneumonia. Serious adverse reactions occurred in 42% of patients, the<br \/>\n      most frequent (\u22652%) of which were urinary tract infection, hematuria,<br \/>\n      acute kidney injury, pneumonia, and urosepsis.\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Adverse reactions<br \/>\n      leading to interruption of KEYTRUDA occurred in 20% of patients; the<br \/>\n      most common (\u22651%) were urinary tract infection (1.5%), diarrhea (1.5%),<br \/>\n      and colitis (1.1%). The most common adverse reactions (\u226520%) in patients<br \/>\n      who received KEYTRUDA vs those who received chemotherapy were fatigue<br \/>\n      (38% vs 56%), musculoskeletal pain (32% vs 27%), pruritus (23% vs 6%),<br \/>\n      decreased appetite (21% vs 21%), nausea (21% vs 29%), and rash (20% vs<br \/>\n      13%). Serious adverse reactions occurred in 39% of KEYTRUDA-treated<br \/>\n      patients, the most frequent (\u22652%) of which were urinary tract infection,<br \/>\n      pneumonia, anemia, and pneumonitis.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      There is limited experience in pediatric patients. In a study, 40<br \/>\n      pediatric patients (16 children aged 2 years to younger than 12 years<br \/>\n      and 24 adolescents aged 12 years to 18 years) with advanced melanoma,<br \/>\n      lymphoma, or PD-L1\u2013positive advanced, relapsed, or refractory solid<br \/>\n      tumors were administered KEYTRUDA 2 mg\/kg every 3 weeks. Patients<br \/>\n      received KEYTRUDA for a median of 3 doses (range 1\u201317 doses), with 34<br \/>\n      patients (85%) receiving KEYTRUDA for 2 doses or more. The safety<br \/>\n      profile in these pediatric patients was similar to that seen in adults<br \/>\n      treated with KEYTRUDA. Toxicities that occurred at a higher rate (\u226515%<br \/>\n      difference) in these patients when compared to adults under 65 years of<br \/>\n      age were fatigue (45%), vomiting (38%), abdominal pain (28%),<br \/>\n      hypertransaminasemia (28%), and hyponatremia (18%).\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b><br \/>\n<br \/>Our goal is to translate<br \/>\n      breakthrough science into innovative oncology medicines to help people<br \/>\n      with cancer worldwide. At Merck, helping people fight cancer is our<br \/>\n      passion and supporting accessibility to our cancer medicines is our<br \/>\n      commitment. Our focus is on pursuing research in immuno-oncology and we<br \/>\n      are accelerating every step in the journey \u2013 from lab to clinic \u2013 to<br \/>\n      potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program evaluating our anti-PD-1 therapy across more than 30<br \/>\n      tumor types. We also continue to strengthen our immuno-oncology<br \/>\n      portfolio through strategic acquisitions and are prioritizing the<br \/>\n      development of several promising immunotherapeutic candidates with the<br \/>\n      potential to improve the treatment of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51788998&amp;newsitemid=20180416005456&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=f10dd29775bfdc86d051ead3f9c698f3\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b><br \/>\n<br \/>For more than a century, Merck, a leading global<br \/>\n      biopharmaceutical company known as MSD outside of the United States and<br \/>\n      Canada, has been inventing for life, bringing forward medicines and<br \/>\n      vaccines for many of the world\u2019s most challenging diseases. Through our<br \/>\n      prescription medicines, vaccines, biologic therapies and animal health<br \/>\n      products, we work with customers and operate in more than 140 countries<br \/>\n      to deliver innovative health solutions. We also demonstrate our<br \/>\n      commitment to increasing access to health care through far-reaching<br \/>\n      policies, programs and partnerships. Today, Merck continues to be at the<br \/>\n      forefront of research to advance the prevention and treatment of<br \/>\n      diseases that threaten people and communities around the world &#8211;<br \/>\n      including cancer, cardio-metabolic diseases, emerging animal diseases,<br \/>\n      Alzheimer\u2019s disease and infectious diseases including HIV and Ebola. For<br \/>\n      more information, visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51788998&amp;newsitemid=20180416005456&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=46639264407d663a4c507b4494238828\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51788998&amp;newsitemid=20180416005456&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=587f388cfcc49f97f9f49133506a4199\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51788998&amp;newsitemid=20180416005456&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=8434c003f43785af9477f258a7b2d41b\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51788998&amp;newsitemid=20180416005456&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=aa520a710a3c37d08155a06e77c31346\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51788998&amp;newsitemid=20180416005456&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=45f0b8bbd314ac799bcfb813445ca897\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51788998&amp;newsitemid=20180416005456&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=8&amp;md5=831dddbe45895028601dec48a46b7bec\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b><br \/>\n<br \/>This<br \/>\n      news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d)<br \/>\n      includes \u201cforward-looking statements\u201d within the meaning of the safe<br \/>\n      harbor provisions of the U.S. Private Securities Litigation Reform Act<br \/>\n      of 1995. These statements are based upon the current beliefs and<br \/>\n      expectations of the company\u2019s management and are subject to significant<br \/>\n      risks and uncertainties. There can be no guarantees with respect to<br \/>\n      pipeline products that the products will receive the necessary<br \/>\n      regulatory approvals or that they will prove to be commercially<br \/>\n      successful. If underlying assumptions prove inaccurate or risks or<br \/>\n      uncertainties materialize, actual results may differ materially from<br \/>\n      those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51788998&amp;newsitemid=20180416005456&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=d89c25ed94955c65a7302d6461c4ee14\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51788998&amp;newsitemid=20180416005456&amp;lan=en-US&amp;anchor=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=10&amp;md5=56729e8d4d7a0686de1658805d378c77\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b><br \/>\n      and<\/b><br \/>\n<br \/>\n<b>Patient Information\/Medication Guide for KEYTRUDA at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51788998&amp;newsitemid=20180416005456&amp;lan=en-US&amp;anchor=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=11&amp;md5=ad0f7a583cac923e7c51703cc596e5f8\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n      ALIMTA<sup>\u00ae<\/sup>&nbsp;is a registered trademark of Eli Lilly and Company.\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180416005456r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Kristen        Drake, 908-334-4688<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>or<br \/>Michael        DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>KEYTRUDA Combination Improved Overall Survival in Patients Regardless of PD-L1 Expression, Including Patients Who Tested Negative for PD-L1 Results Presented Today at AACR 2018 and Published in The New England Journal of Medicine Also Show Significant Improvement in Progression-Free Survival, with Risk of Progression or Death Reduced by Nearly Half Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from KEYNOTE-189, a pivotal Phase 3 trial evaluating KEYTRUDA \u00ae , Merck\u2019s anti-PD-1 therapy, in combination with pemetrexed (ALIMTA \u00ae ) and cisplatin or carboplatin for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC). Findings showed that the KEYTRUDA-pemetrexed-platinum chemotherapy combination significantly improved overall survival (OS), reducing the risk of death by half compared with chemotherapy alone (HR=0.49 [95% CI, 0.38-0.64]; p&lt;0.00001). In pre-specified exploratory analyses, an OS benefit was<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,289,56],"class_list":["post-745734","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Pemetrexed (ALIMTA\u00ae) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Pemetrexed (ALIMTA\u00ae) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study - Merck.com\" \/>\n<meta property=\"og:description\" content=\"KEYTRUDA Combination Improved Overall Survival in Patients Regardless of PD-L1 Expression, Including Patients Who Tested Negative for PD-L1 Results Presented Today at AACR 2018 and Published in The New England Journal of Medicine Also Show Significant Improvement in Progression-Free Survival, with Risk of Progression or Death Reduced by Nearly Half Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from KEYNOTE-189, a pivotal Phase 3 trial evaluating KEYTRUDA \u00ae , Merck\u2019s anti-PD-1 therapy, in combination with pemetrexed (ALIMTA \u00ae ) and cisplatin or carboplatin for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC). Findings showed that the KEYTRUDA-pemetrexed-platinum chemotherapy combination significantly improved overall survival (OS), reducing the risk of death by half compared with chemotherapy alone (HR=0.49 [95% CI, 0.38-0.64]; p&lt;0.00001). In pre-specified exploratory analyses, an OS benefit was\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"26 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a\\\/\",\"name\":\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Pemetrexed (ALIMTA\u00ae) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-04-16T08:30:00+00:00\",\"dateModified\":\"2025-11-07T06:27:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Pemetrexed (ALIMTA\u00ae) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Pemetrexed (ALIMTA\u00ae) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Pemetrexed (ALIMTA\u00ae) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study - Merck.com","og_description":"KEYTRUDA Combination Improved Overall Survival in Patients Regardless of PD-L1 Expression, Including Patients Who Tested Negative for PD-L1 Results Presented Today at AACR 2018 and Published in The New England Journal of Medicine Also Show Significant Improvement in Progression-Free Survival, with Risk of Progression or Death Reduced by Nearly Half Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from KEYNOTE-189, a pivotal Phase 3 trial evaluating KEYTRUDA \u00ae , Merck\u2019s anti-PD-1 therapy, in combination with pemetrexed (ALIMTA \u00ae ) and cisplatin or carboplatin for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC). Findings showed that the KEYTRUDA-pemetrexed-platinum chemotherapy combination significantly improved overall survival (OS), reducing the risk of death by half compared with chemotherapy alone (HR=0.49 [95% CI, 0.38-0.64]; p&lt;0.00001). In pre-specified exploratory analyses, an OS benefit was","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:23+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"26 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a\/","name":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Pemetrexed (ALIMTA\u00ae) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-04-16T08:30:00+00:00","dateModified":"2025-11-07T06:27:23+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-keytruda-pembrolizumab-plus-pemetrexed-alimta-and-platinum-chemotherapy-reduced-the-risk-of-death-by-half-compared-with-chemotherapy-alone-as-first-line-treatment-for-a\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Pemetrexed (ALIMTA\u00ae) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"3131c6ce-52ff-4b09-9846-96a118251ded","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-KEYTRUDA-pembrolizumab-Plus-Pemetrexed-ALIMTA-and-Platinum-Chemotherapy-Reduced-the-Risk-of-Death-by-Half-Compared-with-Chemot-0UNUT.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":3,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745734\/revisions"}],"predecessor-version":[{"id":3675091,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745734\/revisions\/3675091"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745734"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}